Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules, Securing Continued Listing
VANCOUVER, British Columbia – July 22, 2025 – Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage immuno-oncology company, announced today that it has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. This positive development ensures the company’s securities will remain listed on the Nasdaq Stock Market.
The company had previously received a determination from the Nasdaq Listing Qualifications department indicating that its common stock had not maintained the minimum closing bid price of $1.00 per share, as required by Nasdaq Listing Rule 5450(a)(2). Following this notification, Oncolytics Biotech implemented a series of strategic initiatives aimed at bolstering its stock price and demonstrating sustained market confidence.
Oncolytics Biotech successfully achieved compliance with the minimum bid price requirement when its common stock maintained a closing bid price of $1.00 or greater for a minimum of ten consecutive business days. This achievement is a testament to the company’s dedicated efforts and the positive outlook from its investors.
“We are delighted to have regained compliance with Nasdaq’s minimum bid price requirement,” said Dr. Matt Nichol, President and Chief Executive Officer of Oncolytics Biotech. “This milestone is crucial for maintaining our listing on Nasdaq and reflects the ongoing progress we are making in our clinical programs and the inherent value of our innovative platform. We remain committed to our mission of advancing novel cancer therapies and delivering value to our shareholders.”
The Nasdaq Capital Market provides a regulated environment for emerging companies to access public capital markets. Maintaining compliance with its listing standards is essential for Oncolytics Biotech’s ongoing operations and its ability to attract and retain investors.
The company’s lead product candidate, pelareximab (an immunotherapy agent), is currently being evaluated in several clinical trials, including combination studies with checkpoint inhibitors and other therapies for various solid tumors. The positive progress in these trials has contributed to a renewed investor interest, supporting the company’s recent stock performance.
Oncolytics Biotech continues to focus on advancing its robust pipeline and achieving key clinical milestones. The company anticipates further updates on its clinical development programs and strategic initiatives in the coming months.
About Oncolytics Biotech Inc.
Oncolytics Biotech Inc. is a clinical-stage immuno-oncology company focused on developing and commercializing therapies that create a potent and accessible treatment for a wide range of cancers. Oncolytics’ lead product candidate, pelareximab, is a novel immunotherapy agent that is designed to selectively kill cancer cells and stimulate the innate immune system. Pelareximab is currently being evaluated in a number of clinical trials in combination with various cancer therapies, including checkpoint inhibitors, for the treatment of various solid tumors.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the company’s ability to maintain its Nasdaq listing, the progress of its clinical trials, and its future prospects. These statements are based on current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks inherent in the process of developing and commercializing new therapies, the results of clinical trials, the ability to obtain regulatory approvals, the ability to attract and retain investors, and other factors described in Oncolytics Biotech’s filings with the U.S. Securities and Exchange Commission and the Canadian securities regulatory authorities. Oncolytics Biotech undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: [Insert Contact Information if available from the original source]
Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules’ at 2025-07-22 19:32. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.